AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12502940 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual performance
Number of subjects: 61
Study 12502940 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 61
Study 10647800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylnaltrexone
Number of subjects: 22
Study 10647800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 10647800 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 8758162 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflation tool
Number of subjects: 10
Study 8758162 — intervention group
Group type: COMPARATOR
Intervention: Manual deflation
Number of subjects: 10
Study 8758162 — intervention group
Group type: COMPARATOR
Intervention: Free deflation
Number of subjects: 10
Study 1958439 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine 72 mg three times daily
Number of subjects: 0
Study 1958439 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine 5 mg three times daily
Number of subjects: 0
Study 1958439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7150932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole with premedication
Number of subjects: 45
Study 7150932 — intervention group
Group type: COMPARATOR
Intervention: Transrectal biopsy
Number of subjects: 45
Study 7150932 — intervention group
Group type: COMPARATOR
Intervention: Transperineal biopsy
Number of subjects: 45
Study 30931720 — intervention group
Group type: EXPERIMENTAL
Intervention: CSM referral letter + Dental Information Guide (DIG)
Number of subjects: 597
Study 30931720 — intervention group
Group type: EXPERIMENTAL
Intervention: CSM referral letter alone
Number of subjects: 597
Study 30931720 — intervention group
Group type: COMPARATOR
Intervention: Standard letter
Number of subjects: 597
Study 28735928 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant 200 mg
Number of subjects: 709
Study 28735928 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant 100 mg
Number of subjects: 709
Study 28735928 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg (active reference)
Number of subjects: 709
Study 28735928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 709
Study 25720711 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy and rehabilitation training
Number of subjects: 103
Study 25720711 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy, rehabilitation training and botulinum toxin type A injection
Number of subjects: 103
Study 25720711 — intervention group
Group type: EXPERIMENTAL
Intervention: AFO plus conventional therapy and rehabilitation training
Number of subjects: 103
Study 23725204 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir (T) with 24 weeks peginterferon alpha-2a/ribavirin (PR) (T12PR24)
Number of subjects: 722
Study 23725204 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir (T) with 48 weeks peginterferon alpha-2a/ribavirin (PR) (T12PR48)
Number of subjects: 722
Study 23725204 — intervention group
Group type: COMPARATOR
Intervention: 48 weeks of peginterferon alpha-2a/ribavirin (PR)
Number of subjects: 722
Study 23725204 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained virological response (SVR) at week 72
Number of subjects: 722
Study 22081618 — intervention group
Group type: EXPERIMENTAL
Intervention: Mate tea consumption (330 mL, 3 times a day for 60 days)
Number of subjects: 58
Study 22081618 — intervention group
Group type: EXPERIMENTAL
Intervention: Mate tea consumption combined with nutritional counseling
Number of subjects: 58
Study 19843808 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone group (34 mL lidocaine 1.5% with 100 ng naloxone)
Number of subjects: 112
Study 19843808 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone + Fentanyl group (34 mL lidocaine 1.5% with 100 microg fentanyl and 100 ng naloxone)
Number of subjects: 112
Study 19843808 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl group (34 mL lidocaine 1.5% with 100 microg fentanyl)
Number of subjects: 112
Study 19843808 — intervention group
Group type: COMPARATOR
Intervention: Control group (34 mL lidocaine 1.5% with isotonic saline)
Number of subjects: 112
Study 17372325 — intervention group
Group type: COMPARATOR
Intervention: Non-dieting program
Number of subjects: 123
Study 17372325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dieting condition (meal replacement diet and balanced deficit diet combined)
Number of subjects: 123
Study 17372325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dieting and non-dieting groups
Number of subjects: 123
Study 17372325 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in self-esteem
Number of subjects: 123
Study 15201430 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 11517140 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg intravenously at the end of surgery and 8 mg in PCA morphine solution
Number of subjects: 81
Study 11517140 — intervention group
Group type: COMPARATOR
Intervention: Morphine via PCA syringe
Number of subjects: 81
Study 9663812 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 4 mg
Number of subjects: 12
Study 9663812 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg
Number of subjects: 12
Study 9663812 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg
Number of subjects: 12
Study 9663812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8083709 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic blood transfusion
Number of subjects: 120
Study 8083709 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Number of subjects: 120
Study 8083709 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic blood transfusion (2 U or less)
Number of subjects: 120
Study 8083709 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic blood transfusion (adjusted for T and N stage)
Number of subjects: 120
Study 2973300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis with rt-PA immediately followed by transluminal coronary angioplasty (group 1, n = 183)
Number of subjects: 367
Study 2973300 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis alone (group 2, n = 184)
Number of subjects: 367
Study 31652195 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized music intervention (favorite music for 60 minutes, three times a day)
Number of subjects: 50
Study 31652195 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized music intervention
Number of subjects: 50
Study 31652195 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care without music)
Number of subjects: 50
Study 28647541 — intervention group
Group type: EXPERIMENTAL
Intervention: Response tailored duration of dual sofosbuvir/daclatasvir treatment (8 or 12 weeks based on vRVR)
Number of subjects: 120
Study 28647541 — intervention group
Group type: COMPARATOR
Intervention: Fixed 12 weeks duration of dual sofosbuvir/daclatasvir treatment
Number of subjects: 120
Study 25280085 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib (R788) 100 mg BID
Number of subjects: 0
Study 25280085 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib (R788)
Number of subjects: 0
Study 23459567 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (12 mg or 24 mg)
Number of subjects: 334
Study 23459567 — intervention group
Group type: COMPARATOR
Intervention: IFNB-1a
Number of subjects: 334
Study 21831004 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based high intensity exercise training
Number of subjects: 80
Study 21831004 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 19058679 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Protect Primer applied gently (inactive) + Clearfil Protect Bond
Number of subjects: 40
Study 19058679 — intervention group
Group type: COMPARATOR
Intervention: 38% phosphoric acid for 15 s, rinsed 15 s, and dried 15 s + Clearfil Protect Primer applied gently (inactive) + Clearfil Protect Bond
Number of subjects: 40
Study 19058679 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Protect Primer applied with agitation by microapplicator brush (active) + Clearfil Protect Bond
Number of subjects: 40
Study 19058679 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% phosphoric acid for 15 s, rinsed 15 s, and dried 15 s + Clearfil Protect Primer applied with agitation by microapplicator brush (active) + Clearfil Protect Bond
Number of subjects: 40
Study 16871129 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS XR 20 mg/day
Number of subjects: 255
Study 16871129 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS XR 40 mg/day
Number of subjects: 255
Study 16871129 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS XR 60 mg/day
Number of subjects: 255
Study 16871129 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS XR (all doses)
Number of subjects: 255
Study 16871129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 14668006 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of mifepristone every 2 weeks for 24 weeks
Number of subjects: 20
Study 14668006 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 2 weeks for 24 weeks
Number of subjects: 20
Study 10952230 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 15.3
Number of subjects: 192
Study 10952230 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 192
Study 10952230 — intervention group
Group type: EXPERIMENTAL
Intervention: TPA
Number of subjects: 192
Study 9395376 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) therapy, 3 MU, 3 times a week for 6 months
Number of subjects: 23
Study 9395376 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) therapy, 3 MU, 3 times a week for 12 months
Number of subjects: 23
Study 9395376 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) therapy
Number of subjects: 23
Study 8236464 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil daily (PROG)
Number of subjects: 203
Study 8236464 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine once weekly (CQ)
Number of subjects: 203
Study 8236464 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Chloroquine and Proguanil (CQ+PROG)
Number of subjects: 203
Study 8236464 — intervention group
Group type: COMPARATOR
Intervention: Maternal titres vs cord titres
Number of subjects: 203
Study 8236464 — intervention group
Group type: COMPARATOR
Intervention: Caesarean section or placenta weight between 0.75 and 1 kg
Number of subjects: 203
Study 8236464 — intervention group
Group type: COMPARATOR
Intervention: Cord titres at birth
Number of subjects: 203
Study 3891642 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol plus beclomethasone dipropionate
Number of subjects: 30
Study 3891642 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol
Number of subjects: 30
Study 29540410 — intervention group
Group type: EXPERIMENTAL
Intervention: Patella mobilisation therapy (PMT) with three manual mobilisation sessions and home-based vastus medialis oblique muscle exercise at 2-month intervals
Number of subjects: 208
Study 29540410 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group receiving usual care
Number of subjects: 208
Study 26695005 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Empowerment training sessions
Number of subjects: 589
Study 24763929 — intervention group
Group type: EXPERIMENTAL
Intervention: VR exercises that challenged balance (eg, soccer goaltending, snowboarding) performed while standing
Number of subjects: 59
Study 24763929 — intervention group
Group type: COMPARATOR
Intervention: Exposure to identical VR environments but whose games did not challenge balance (performed in sitting)
Number of subjects: 59
Study 22568118 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus bBTi (4 weekly 1-hour individual sessions)
Number of subjects: 37
Study 19768767 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-Sweat
Number of subjects: 94
Study 19768767 — intervention group
Group type: COMPARATOR
Intervention: Mayo-QSART
Number of subjects: 94
Study 17233546 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis medications (e.g., Bisphosphonates)
Number of subjects: 0
Study 17233546 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies to increase adherence (e.g., reducing administration frequency, monitoring patients, providing instructions)
Number of subjects: 0
Study 17233546 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adherence factors (e.g., adverse effects, pain, uncertainty about BMD test results)
Number of subjects: 0
Study 15618034 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 200
Study 15618034 — intervention group
Group type: COMPARATOR
Intervention: No abciximab
Number of subjects: 200
Study 12449520 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding of low‐residue diets 6 h post‐operatively (n = 95)
Number of subjects: 182
Study 12449520 — intervention group
Group type: COMPARATOR
Intervention: Traditional dietary management of clear liquids once normal bowel sounds were heard (n = 87)
Number of subjects: 182
Study 10458007 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 10458007 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 60
Study 7872931 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit memory (tachistoscopic identification)
Number of subjects: 32
Study 7872931 — intervention group
Group type: COMPARATOR
Intervention: Explicit memory (recognition)
Number of subjects: 32
Study 2222172 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol groups using supranormal cardiac index, oxygen delivery, and oxygen consumption values as goals
Number of subjects: 2
Study 2222172 — intervention group
Group type: COMPARATOR
Intervention: Control groups using normal values as therapeutic goals
Number of subjects: 2
Study 240481 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol (200 mg twice daily)
Number of subjects: 3038
Study 31810418 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (QIV) in thiomersal-containing multi-dose vial (MDV) format
Number of subjects: 302
Study 31810418 — intervention group
Group type: COMPARATOR
Intervention: Licensed thiomersal-free pre-filled syringe (PFS) format
Number of subjects: 302
Study 30467686 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin + Clopidogrel
Number of subjects: 334
Study 30467686 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin + Ticagrelor
Number of subjects: 334
Study 30467686 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin + Clopidogrel + Cilostazol
Number of subjects: 334
Study 28854085 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 9340
Study 28854085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9340
Study 25925203 — intervention group
Group type: EXPERIMENTAL
Intervention: IV amino acid therapy (up to 100 g daily)
Number of subjects: 474
Study 25925203 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 474
Study 23948391 — intervention group
Group type: EXPERIMENTAL
Intervention: overnight storage with alkaline peroxide-based cleansing tablet
Number of subjects: 51
Study 23948391 — intervention group
Group type: COMPARATOR
Intervention: dry storage
Number of subjects: 51
Study 23948391 — intervention group
Group type: COMPARATOR
Intervention: overnight storage in water
Number of subjects: 51
Study 21273617 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel (repeated every 3 weeks)
Number of subjects: 61
Study 21273617 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus vinorelbine (repeated every 3 or 4 weeks)
Number of subjects: 61
Study 21273617 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus paclitaxel (repeated every 4 weeks)
Number of subjects: 61
Study 19758415 — intervention group
Group type: EXPERIMENTAL
Intervention: James' blinding index (BI)
Number of subjects: 0
Study 19758415 — intervention group
Group type: EXPERIMENTAL
Intervention: Bang's BI
Number of subjects: 0
Study 19758415 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 16446400 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure changes during the video game task
Number of subjects: 2816
Study 16446400 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure changes during the star tracing task
Number of subjects: 2816
Study 15451900 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin (premeal inhaled insulin plus a bedtime dose of Ultralente)
Number of subjects: 299
Study 15451900 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin (at least two daily injections of mixed regular/NPH insulin)
Number of subjects: 299
Study 15451900 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin
Number of subjects: 299
Study 15451900 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin
Number of subjects: 299
Study 11054332 — intervention group
Group type: EXPERIMENTAL
Intervention: INTACS (KeraVision, Inc.)
Number of subjects: 165
Study 9229982 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal-flow anaesthesia with desflurane (0.5 l/min fresh gas flow)
Number of subjects: 106
Study 9229982 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow anaesthesia with desflurane (1.0 l/min fresh gas flow)
Number of subjects: 106
Study 9229982 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow phase with desflurane (4.4 l/min fresh gas flow)
Number of subjects: 106
Study 8153919 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mmol/day slow sodium
Number of subjects: 27
Study 8153919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 3524549 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter
Number of subjects: 82
Study 3524549 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin F2 alpha in Tylose gel
Number of subjects: 82
Study 29447780 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprimary PCI at hospitals without cardiac surgery on-site (SoS)
Number of subjects: 0
Study 29447780 — intervention group
Group type: COMPARATOR
Intervention: Elective PCI at an SoS hospital
Number of subjects: 0
Study 26511939 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin 100 µgm
Number of subjects: 100
Study 26511939 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin 5 IU
Number of subjects: 100
Study 26511939 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin
Number of subjects: 100
Study 26511939 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 100
Study 26511939 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin and Oxytocin
Number of subjects: 100
Study 24453500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) treatment at 42°C for 120 seconds to the dorsal root ganglion (DRG)
Number of subjects: 32
Study 24453500 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (needle placement)
Number of subjects: 32
Study 24453500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) treatment
Number of subjects: 32
Study 22840612 — intervention group
Group type: EXPERIMENTAL
Intervention: The Little Prince is Depressed (LPD) programme, a 12-week school-based face-to-face programme with psycho-educational lessons and homework assignments.
Number of subjects: 0
Study 22840612 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 20495521 — intervention group
Group type: EXPERIMENTAL
Intervention: Medina classification
Number of subjects: 0
Study 20495521 — intervention group
Group type: EXPERIMENTAL
Intervention: Movahed classification
Number of subjects: 0
Study 18341520 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 169
Study 18341520 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 169
Study 15701498 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference lectures
Number of subjects: 110
Study 15701498 — intervention group
Group type: COMPARATOR
Intervention: Conventional lectures
Number of subjects: 110
Study 12190752 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (0.2‐0.4 micro g.kg‐1.min‐1)
Number of subjects: 50
Study 12190752 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl bolus (3 micro g.kg‐1) + propofol infusion (2 mg.kg‐1.h‐1)
Number of subjects: 50
Study 10598608 — intervention group
Group type: EXPERIMENTAL
Intervention: COPA with a millimeter microchip sensor
Number of subjects: 20
Study 10598608 — intervention group
Group type: COMPARATOR
Intervention: COPA with a fiberoptic scope
Number of subjects: 20
Study 8583804 — intervention group
Group type: EXPERIMENTAL
Intervention: Neodymium:yttrium aluminum garnet contact laser surgery (n = 33)
Number of subjects: 72
Study 8583804 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled lung reduction surgery (n = 39)
Number of subjects: 72
Study 1902363 — intervention group
Group type: EXPERIMENTAL
Intervention: Water bed
Number of subjects: 6
Study 1902363 — intervention group
Group type: COMPARATOR
Intervention: King's Fund bed
Number of subjects: 6
Study 6211167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms)
Number of subjects: 10
Study 6211167 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (500 micrograms)
Number of subjects: 10
Study 6211167 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine methonitrate (2 mg) as a wet aerosol
Number of subjects: 10
Study 6211167 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ipratropium bromide and terbutaline
Number of subjects: 10
Study 6211167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6211167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide and terbutaline combination
Number of subjects: 10
Study 30927859 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical simulations using a mathematical model of glycolytic oscillations
Number of subjects: 0
Study 30927859 — intervention group
Group type: EXPERIMENTAL
Intervention: Log-normal distribution of the maximum uptake velocity of glucose and four randomized rate constants
Number of subjects: 0